Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal [Globe and Mail, The (Toronto, Canada)]
OSR Holdings, Inc. (OSRH)
Company Research
Source: Globe and Mail, The
Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology. Shares of OSR Holdings, Inc. ( NASDAQ: OSRH ) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform. The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-thro
Show less
Read more
Impact Snapshot
Event Time:
OSRH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OSRH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OSRH alerts
High impacting OSR Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
OSRH
News
- Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement [Yahoo! Finance]Yahoo! Finance
- OSR (NASDAQ:OSRH) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months [Yahoo! Finance]Yahoo! Finance
- Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three MonthsPR Newswire
- OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 [Yahoo! Finance]Yahoo! Finance
OSRH
Sec Filings
- 11/25/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 10/24/25 - Form 3
- OSRH's page on the SEC website